Michael Ero

Mr. Ero is the CEO of Machaon Diagnostics, a company he founded in 2003. He has built a solutions-based, team approach to laboratory medicine, designing new and innovative laboratory strategies to meet unmet needs in the healthcare and bioscience industries. He is a laboratory expert with over 25 years of healthcare experience. Mr. Ero leads a team with over 400 aggregate years of experience in specialized laboratory diagnostics and genetics. Under his leadership, Machaon Diagnostics’ scientists and physicians have pioneered multiple disruptive laboratory techniques and processes that have revolutionized how life-threatening diseases can be managed and characterized. Machaon Diagnostics has been the contract laboratory or primary contract research organization (CRO) on over 250 clinical trials and studies with physical, molecular, immunologic, platelet and special coagulation endpoints. Clients include Fortune 500 pharmaceutical and biotechnology firms and large academic medical centers, hospital systems, multinational CROs and national/international reference laboratories. Mr. Ero speaks regularly at national and international scientific conferences and has over 30 scientific publications.

Prior to founding Machaon Diagnostics, Mr. Ero was vice president of the Coagulation Center, Inc. of Oakland, California prior to its acquisition by Quest Diagnostics (NYSE:DGX). He has held past clinical and research roles with The Scripps Research Institute, Loyola University Medical Center and the University of Illinois, Chicago. Mr. Ero is the founder and board chairman of Labs4Free, a charitable organization (501c3) that provides laboratory services to underserved populations.

He holds an MBA from Babson College, a certificate in Healthcare Strategy from Harvard Business School and a BS in medical technology from Michigan State University. He is a licensed clinical laboratory scientist (CLS) and a board-certified (ASCP) medical technologist. Mr. Ero has been an inspector for the College of American Pathologists (CAP) for over 20 years. He is also a good laboratory practices (GLP) auditor and an FDA and EMA regulatory affairs consultant.